Table 1.
Clinical studies 2014–2021.
| Study | Pt. Number |
Country | Patient Selection | Embolic Agent | Median FU | Complication | Outcome (% of No/Unsatisfactory Clinical Success) |
|---|---|---|---|---|---|---|---|
| Vidal 2014 | 14 | Goligher’s Grade II or IV | Coils | 6 months | none | 28% | |
| Zakharchenko 2016 | 40 | France | Goligher’s Grade I to III | Coils + PVA | 1 month | none | 6–17% |
| Moussa 2016 | 30 | France | Goligher’s Grade I to IV | Coils | 5 months | none | 28% |
| Tradi 2018 | 25 | France | Goligher’s Grade II or III | Coils | 12 months | none | 28% |
| Giurazza 2020 | 5 | Italy | portal hypertension and chronic hemorrhoidal bleeding | Colis | 3 months | none | 20% |
| Abd El Tawab 2020 | 33 | Egypt | Goligher’s Grade II or III | TAGp | 12 months | none | 3% |
| Moussa 2020 | 38 | France | Goligher’s Grade II or III | Coils + TAGp | 6 months | 15.00% | 34.00% |
| Küçükay 2021 | 42 | Turkey | Goligher’s Grade I or IV | TAGp | 12 months | 54% | 7% |
PVAp: polyvinyl alcohol particles; TAGp: tris-acryl gelatin particles.